Company: NCEL
Filing Date: 2025-01-31
Form Type: 6-K
Source: 0001213900-25-008826
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-01-31
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2025 (Report No. 8)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Amendment to the Merger Agreement

On January 30, 2025, NLS Pharmaceutics Ltd. (the “Company”)
entered into an amendment (the “Amendment”) to the Agreement and Plan of Merger, dated November 4, 2024 (the “Merger
Agreement”) among the Company, Kadimastem Ltd. (“Kadimastem”) and NLS Pharmaceutics (Israel) Ltd. (collectively, the
“Parties”).

Pursuant to the Amendment, the Parties agreed to extend the Merger Agreement’s
termination date from January 31, 2025 to April 30, 2025 in order to complete the merger. The Amendment further provides that any shareholder
receiving common shares, par value CHF 0.03 per share (the “Common Shares”), in excess of the Beneficial Ownership Limitation
(as defined in the Merger Agreement) as a result of the Merger, shall be issued instead pre-funded warrants exercisable for a number of
Common Shares equal to such Common Shares in excess of the Beneficial Ownership Limitation, at an exercise price equal to the par value
of the Common Shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001 per share.

The
Parties remain focused on and fully committed to aligning their efforts to completing the merger as soon as possible and with the utmost
diligence. The Parties are actively working to fulfill all commitments related to the process and adhere to the requirements set forth
by all regulatory